BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9332768)

  • 1. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
    Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
    Keohavong P; DeMichele MA; Melacrinos AC; Landreneau RJ; Weyant RJ; Siegfried JM
    Clin Cancer Res; 1996 Feb; 2(2):411-8. PubMed ID: 9816185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
    Sugio K; Ishida T; Yokoyama H; Inoue T; Sugimachi K; Sasazuki T
    Cancer Res; 1992 May; 52(10):2903-6. PubMed ID: 1581907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
    Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
    N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
    Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.
    Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR
    Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.